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ABSTRACT
Allergic asthma is a serious socioeconomic and health issue that is characterized
by chronic inflammation of the lungs and affects as many 300 million people worldwide
of all ages. Inhaled environmental factors, such as allergens, can disrupt the airway
epithelium, which is the physical barrier and the first line of defense against external
irritants. Consequently, exposure to allergens can cause episodes of airway inflammation,
increased mucus production and tissue remodeling, that leads to the obstruction and
narrowing of the airways, which may present as difficulty breathing, wheezing, and
persistent coughing. Unfortunately, there is no cure for allergic asthma, but allergen
avoidance and prescription of medication can help manage symptoms. However, current
treatment options fail in almost 10% of patients, making it necessary to study
uncharacterized molecular causes to better understand this condition.

Evidence suggests that mitochondria play a vital role in lung health and disease.
Mitochondria are dynamic organelles that can change in size, shape, and distribution
depending on cellular demands and are transported through the cell on microtubules.
Miro1, a calcium-binding membrane-anchored GTPase that is strongly associated with
mitochondrial transport, is the primary adaptor protein required for the subcellular
positioning of this organelle. While mitochondria play an important role in lung
physiology, the role of localized mitochondrial function in response to allergen-induced
inflammation remained unknown.

The main goal of this study was to investigate the effects Miro1-mediated
mitochondrial trafficking in allergen-induced inflammation and provide a comprehensive
phenotypic readout. To achieve this, our laboratory developed a novel tissue-inducible
mouse model that allowed for the deletion of Miro1 from club cells, an abundant
epithelial cell subtype in mice, and utilized this system with an established model of
chronic allergen-induced inflammation. Our results show that epithelial deletion of Miro1
leads to a heightened inflammatory response, enhanced mucus metaplasia, pronounced
tissue remodeling and smooth muscle levels that leads to increased airway
hyperresponsiveness following chronic exposure to a complex allergen. Results from this
study indicate a possible role for Miro1 in the development and progression of allergic
asthma, providing insights into the role of Miro1-mediated mitochondrial positioning in
allergic asthma severity. Future studies should be conducted to gain a better
understanding of the mechanisms of Miro1 and mitochondrial positioning in asthma.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1. Allergic Asthma
Asthma is a chronic inflammatory condition of the airways that affects as many as
300 million people of all ages worldwide, including 25 million Americans (about 8.5% of
the United States’ population), and accounts for approximately 400,000 deaths annually
[1-3]. The incidence, prevalence, morbidity, and mortality of asthma varies among
populations and ancestral origins possibly due to the influence of gene-by-environment
interactions, concomitant atopy, and social determinants of health [4, 5]. Asthma imposes
substantial burdens on healthcare systems and causes annual economic costs of over $80
billion dollars in the United States [6]. Generally, asthma presents with intermittent and
reversible episodes, or “attacks,” of wheezing, cough, shortness of breath, dyspnea, and
chest tightness often accompanied by expiratory airflow limitation [7]. Asthma
exacerbations are often triggered by factors such as allergen exposure and viral
respiratory infections [8]. Airflow limitation can be attributed to a combination of airway
smooth muscle contraction, inflammation, edema, and fibrosis, and the presence of
excess mucus in the airway lumen [9, 10]. Moreover, airway narrowing in response to
bronchoconstriction and chronic inflammation are associated with asthma and often
persist when a patient is asymptomatic, but may normalize with treatment [11, 12].
Unfortunately, there is no cure for asthma; avoidance of triggers and the use of
bronchodilators and anti-inflammatory drugs such as inhaled rapid-acting β-2 adrenergic
agonists and oral corticosteroids are commonly recommended for the management of
symptoms. However, these current treatment options fail in 5% to 10% of patients or
have serious side effects [13, 14].
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Asthma is a complex, heterogenous condition as suggested by unbiased
clustering-based approaches, which have identified subgroups of individuals with asthma
that share certain characteristics such as age of onset, atopic status, body mass, and
frequency of exacerbations [15-17]. The majority of asthmatics have co-existing atopic
conditions such as allergic rhinitis, atopic dermatitis, or chronic rhinosinusitis [18, 19]. In
addition to elevated concentrations of immunoglobulin E (IgE) associated with atopy,
individuals with asthma can also present with elevated levels of eosinophils in serum,
sputum, and airway tissue [20, 21]. Some asthma phenotypes include allergic
(eosinophilic) asthma, obesity-related asthma, exercise-induced asthma, adult-onset
asthma, and steroid-responsive asthma [22, 23]. Moreover, these phenotypes can be
further subdivided based on specific biological mechanisms. Dysregulation of eicosanoid
mediators and T helper type 2 (Th2) immune responses are examples of pathways
important in specific endotypes [24, 25]. The best recognized asthma endotype is Th2high asthma. In individuals with Th2-high asthma, type 2 cytokines such as interleukin-4
(IL-4), IL-5, and IL-13 are secreted by immune cells including innate lymphoid cells and
CD4+ T cells [26]. These pro-inflammatory cytokines mediate the attraction of
granulocytes like eosinophils, basophils, and mast cells, the secretion of IgE from B cells,
and the activation of smooth muscle cells, fibroblasts, and epithelial cells to produce the
characteristic features of allergic asthma [27].
Allergic asthma is the most common asthma phenotype, representing upwards of
80% of all persistent asthma cases [28]. This asthma phenotype is often induced by early
life encounters with inhaled allergens such as house dust mite, animal dander, mold, and
pollen [29]. Allergen sensitization is thought to have a significant role in the development
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of allergic asthma [30]. Accordingly, the crosstalk between the innate and adaptive
immune systems is crucial for the initiation and propagation of the allergic immune
response [31, 32]. Although allergen-specific IgE responses play a significant role in
allergic asthma, Th2 cytokines are considered the main drivers of the inflammatory
response. Exacerbations in allergic asthma are typically associated with allergen exposure
[8]. Repeated exposure to an allergen leads to the hallmark features of allergic asthma
such as eosinophilic inflammation, bronchoconstriction, airway hyperresponsiveness,
increased mucus production, and airway remodeling (Figure 1).

Figure 1. The Hallmark Features of Allergic Asthma
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1.2. The Airway Epithelium in Allergic Asthma
The lung’s respiratory tract is a branching structure, dividing from the trachea to
the alveoli. The lower airways, including the trachea, bronchi, and bronchioles, can be
divided into the conducting airway zone, transporting inhaled air, and a respiratory acinar
zone, involved mainly in gas exchange. Through the entirety of the airways structure
there is a continuous lining, called the airway epithelium, which plays a significant role in
maintaining the conduit of air to and from the alveoli [33]. It is often thought as a
physical barrier and the first line of defense against inhaled microbes, noxious agents,
and allergens between the host and its environment via secretion of substances such as
surfactant proteins, mucus, and antimicrobial peptides and facilitation of mucocialiary
clearance [34]. However, due to its structure and diverse composition of cells, it also
plays a role in lung fluid balance, temperature control, regulation of smooth muscle cells,
and initiating innate and adaptive immune responses [33]. Moreover, the airway
epithelium is the site of contact for both physical and inflammatory environmental
stimuli.

Consequently,

airway

epithelial

damage

can

contribute

to

the

bronchoconstriction, inflammation, and remodeling changes seen in allergic asthma [35].

1.2.1. Structure and Function of Airway Epithelial Cells
The airway epithelium is lined with an array of specialized cells that fulfil critical
functions related to tissue homeostasis. There have been 10-12 morphologically distinct
epithelial cell types described in the airway epithelium including long and small ciliated,
basal, non-ciliated secretory (goblet, Clara cell, surface serous, submucosal serous, and
submucosal mucous), pulmonary neuroendocrine, brush, and alveolar type I and type II
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cell types [36, 37]. However, based on functional and biochemical criteria, airway
epithelial cells can be classified generally as basal, ciliated, and secretory cells [33, 38].
The four airway epithelial cell types of interest are basal, mucus-secreting (Goblet),
ciliated, and particularly club (Clara) cells (Figure 2).

Figure 2. The Airway Epithelium and its Cells

Basal Cells
Basal cells are ovoid in shape, have a prominent nuclei that fill most of the cell,
and contain a sparse, electron-dense cytoplasm with bundles of low-molecular weight
cytokeratin [39]. These cells are expressed ubiquitously throughout the conducting
airway epithelium and are the only cell type within the airway epithelium to be rigidly
attached to the basement membrane through hemidesmosome complexes [40, 41]. They
form a monolayer along the basement membrane and provide the foundation for
attachment to more superficial cells via desmosome attachments [40]. As such, they are
5

responsible for the pseudostratified appearance of the upper airways. However, the
number of these cells decreases with airway size and the epithelium becomes columnar or
cuboidal [42]. Functionally, basal cells can generate inflammatory responses by secreting
cytokines, coordinate transepithelial water movement, and oxidant defense [43]. Still, the
most important feature of basal cells is their primary stem cell potential in repopulating
all the major epithelial cell types during regeneration and repair [44, 45].

Mucus-secreting (Goblet) Cells
Mucus-secreting epithelial cells have a wide, enlarged apical portion with a
narrow, tapered basal cytoplasm. The nuclei are typically compressed at the basal side of
the cell. The cytoplasm in mucus-secreting cells is relatively dense and electron opaque
due to the numerous membrane-bound acid-mucin granules located at the apical region of
the cell. This cell type is often found in the trachea, bronchi, and bronchioles [46-48].
Their main functions include the secretion of mucus, antimicrobial peptides, surfactant
proteins, chemokines, and cytokines [49, 50]. Under homeostatic conditions, mucussecreting cells, along with the submucosal glands, secrete high-molecular weight mucus
glycoproteins to trap foreign particles in the airway lumen and protect the epithelial
surface. Proper regulation and production of the amount and viscoelasticity of mucin
secretions is essential for normal functioning [51]. Overproduction of mucus can clog the
airways, while underproduction can hinder mucocialiary clearance [52]. Mucus-secreting
cells are capable of self-renewal and can differentiate into ciliated epithelial cells [53].
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Ciliated Cells
Ciliated cells are a major epithelial cell type, accounting for over 50% of all
epithelial cells and lining the trachea and respiratory bronchioles [38]. These cells are
columnar in shape and covered with cilia, with approximately 300 cilia found at the
luminal surface of each cell [54]. Ciliated cells are attached to the basal lamina of the
basement membrane via desmosomes and extend to the luminal side, where they are
interconnected via tight junctions [37]. This cell type lacks mucus granules and secretory
products. Many mitochondria are found at the apical pole of the cell, immediately under
the row of basal bodies to which the cilia are attached, emphasizing the primary role of
ciliated cells in the transport of mucus from the lungs to the throat [33, 55]. Ciliated cells
play a significant role in repair of distal airway injury. As a result, ciliary dysfunction and
ultrastructural abnormalities have been associated with asthma severity [56]. It has been
shown that ciliated cells stem from basal or club cells, and until recently were considered
to be terminally differentiated cells [33, 53].

Club (Clara) Cells
Club cells protrude above ciliated cells and are cuboidal in shape with a basally
located nucleus, prominent Golgi apparatus, abundant organelles such as agranular and
granular endoplasmic reticulum, and many membrane-bound electron-dense secretory
granules. Atypical mitochondria with no cristae and an abundant pale matrix localize at
the apical portion of club cells. These non-ciliated secretory cells are located in the
terminal and respiratory bronchioles [46, 57]. Unlike mucus-secreting cells, the secretory
granules do not contain glycoproteins. Club cells are metabolically active and can secrete
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CC10 (or CCSP), a secreted protein important for regulating the inflammatory response,
surfactant apoproteins A, B, and D, proteases, antimicrobial peptides, several cytokines
and chemokines [58]. Moreover, they aid in several chemical and physical lung
protective functions such as detoxifying xenobiotics and oxidant gases, regulating
inflammation, and contributing to mucocialiary clearance [57, 59]. In addition to their
secretory role, club cells have the ability to self-renew and function as stem cells, serving
as the progenitor for both ciliated and mucus-secreting cells to repopulate damaged
airway tissue [60].

1.2.2. Allergen-induced airway responses
HDM-induced airway inflammation
Environmental allergens, such as house dust mites (HDM), are a the most relevant
driver of disease in allergic asthma. HDM represent one of the most common sources of
inhaled allergens, with more than 50% of atopic individuals sensitized to its allergenic
peptides [61]. The primary allergenic particles of HDM are found within the fecal waste
pellets, but HDM also contain an array of allergens packaged with bacterial DNA,
endotoxin, and chitin that have proteolytic activity and can induce immune responses by
acting as pathogen associated molecular patterns (PAMPs) [62]. Proteins found in
allergens such as Der p1, a cysteine protease, and Der p2, a ligand binding to endotoxin
receptors such as toll-like receptor 4 (TLR-4), have the highest rates of sensitization [6264]. When in contact with the airway epithelium, the allergen-containing particles of
HDM promote sensitization and atopic responses and changes to the airway epithelium
[65].
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Atopy arises as a consequence of a combination of both epithelial barrier
dysfunction and a heightened immunologic response [66]. Being the first line of defense
against allergens, the airway epithelium is equipped with protease-activated receptors
(PARs) and pattern-recognition receptors (PRRs) to detect the active allergenic
components of HDM such as proteases and PAMPs, respectively [65, 67]. HDM
proteases, such as Der p1, directly stimulate PARs in the bronchial epithelium of
asthmatics and disrupt the tight junctions between the airway epithelial cells, allowing the
infiltration of the allergenic particles into the subepithelial tissue [68, 69]. Moreover, Der
p2 and other components of HDM such as bacterial DNA, endotoxin, and chitin can
initiate innate immune responses via PRRs such as TLR-4 [64]. Activation of PRRs in
airway epithelial cells by HDM allergens leads to the recruitment and activation of
antigen presenting cells, including dendritic cells and macrophages, through the release
of chemokines and cytokines by epithelial cells such as CCL20, IL-25, IL-33, thymic
stromal lymphopoietin (TLSP), and granulocyte-macrophage colony-stimulating factor
(GM-CSF) [67, 70, 71]. Dendritic cells link the innate and adaptive immune responses,
facilitating and promoting the inflammatory process in the airway epithelium. Infiltrated
HDM allergens are processed by tissue resident antigen presenting cells. Once matured,
these antigen presenting cells present the processed allergen particles to naïve T
lymphocytes in the draining lymph nodes of the lung [72]. Furthermore, activated T
lymphocytes signal to antigen presenting cells to produce Th2 cytokines that recruit,
mature, and activate eosinophils such as IL-3, IL-4, IL-5, and IL-13 [61]. Secretion of
Th2 cytokines promotes airway inflammation and the immunoglobulin isotype switching
from IgG to IgE, leading to the production of allergen-specific IgE, which eventually
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bind to receptors in mast cells, basophils, and eosinophils [67]. Consequently, later
encounters with HDM allergens will result in an immediate hypersensitivity phase where
mast cells and basophils are degranulated, a late inflammatory phase where newly
synthesized pro-inflammatory mediators are synthesized and secreted, and a chronic
phase with hypersensitive responses [61]. Prolonged immune responses are key drivers in
allergic asthma and have detrimental effects to the airways such as hyperresponsiveness
and remodeling [73].

HDM-induced airway remodeling
Airway remodeling is the repair process following chronic airway injury and
subsequent airway inflammation. In allergic asthma, airway remodeling is considered the
result of chronic bronchial inflammatory insults from an allergen exposure in sensitized
individuals. Upon epithelial damage from exposure to allergens, the epithelial barrier is
disrupted, promoting the release of cytokines and chemokines such as IL-4 and IL-13, as
well as the release of growth factors including epidermal growth factor (EGF) [74],
transforming growth factor beta (TGF-β) [75], and vascular endothelial growth factor
(VEGF) [76]. Consequently, airway remodeling is characterized by changes in the
molecular, cellular, and tissue composition of the airway epithelium. Some of the
structural changes associated with airway remodeling include disrupted epithelial
integrity and basement membrane thickening, goblet cell hyperplasia/metaplasia, smooth
muscle hypertrophy/hyperplasia, subepithelial fibrosis, and angiogenesis [77]. Airway
remodeling

is

an

intractable

problem
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in

asthma,

contributing

to

airway

hyperresponsiveness, airflow limitation, and progressive or irreversible loss of lung
function.

Epithelial Barrier Dysfunction. Epithelial damage is a pathological feature observed in
all phenotypes of asthma, with epithelial changes and disruption occurring during the
pathogenesis of asthma [49]. Inability to regain epithelial barrier function as a result of Ecadherin degradation via EGFR activation can result in increased permeability to
allergens, the propagation of downstream pro-inflammatory responses via secretion of
CCL20 and GM-CSF, and abnormal repair through impaired re-differentiation of
epithelial cells [78-81]. Moreover, continual loss of E-cadherin can activate β-catenin
processes that cause additional loss of epithelial characteristics, the induction of more
basal and mesenchymal phenotypes, as well as goblet cell hyperplasia with loss of
ciliated cells [78].

Subepithelial Fibrosis. Fibroblasts are large, flat cells that reside around the lamina
reticularis, just below the epithelial basement membrane. In inflammatory environments
such as asthmatic airways, cytokines such as IL-4, IL-13, and GM-CSF, growth factors
like TGF-β, PDGF, and bFGF, and other mediators such as histamine, tryptase, and
thrombin can activate and induce fibroblast differentiation into myofibroblasts [82]. In
asthmatic individuals, increased susceptibility to injury and abnormal repair responses
result in persistent fibroblast activation [83]. Myofibroblasts are a key cell in the fibrotic
response due to the secretion of pro-inflammatory mediators and extracellular matrix
proteins, including collagens type I, III, and V, fibronectin, tenascin, lumican, and
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biglycan [84]. Moreover, the synthesis and degradation of the extracellular matrix
compartment in the airway wall is dynamic. A shift toward excess matrix deposition
results in fibrosis, leading to alterations in the structure and function of the airways [85].
Subepithelial fibrosis has been linked to asthma severity with higher collagen expression
in those with moderate to severe asthma when compared to those with mild disease [8688]. Furthermore, the degree subepithelial fibrosis is inversely correlated with forced
expiratory volume in one second (FEV1), a measure of lung function [86]. Increased
subepithelial fibrosis in the small airways in asthma can lead to airway narrowing and
obstruction [89].

Goblet Cell Hyperplasia/Metaplasia. IL-4 and IL-13 are key drivers in the Th2 immune
responses of allergic asthma. IL-4 is mainly involved in Th2 cell differentiation,
immunoglobulin class switching, and eosinophil trafficking, while IL-13 promotes IgE
synthesis and goblet cell hyperplasia [90, 91]. In healthy lungs, goblet cells are present
sparingly throughout the small airways. Goblet cell hyperplasia and metaplasia have been
described in both the small and large airways of asthmatics [92-94]. Differentiation of
club cells and ciliated cells into goblet cells is the main mechanism for goblet cell
metaplasia [65]. Goblet cell changes in the peripheral, small airways contribute to a
greater extent to disease because the clearance of mucus from the small airways appears
to be more difficult when compared to the more central, larger airways [92, 95]. The key
role of mucus in the airways is to form a protective layer between the external and
internal environment [96]. The viscoelastic features of mucus are strongly associated with
mucins, high molecular-weight glycoproteins, with MUC5AC and MUC5B being the

12

predominant mucins in airway secretions [97]. In healthy small airways, MUC5AC is not
observed [98], but it is upregulated in the small airways of those with asthma [99]. The
increased amount of mucus within the luminal space can also be attributed to the
hindrance of the mucocialiary escalator, with factors such as abnormal ciliary function
resulting in reduced clearance [56]. Epithelial compression due to bronchoconstriction is
also thought to induce goblet cell hyperplasia and metaplasia with subsequent mucus
production [100].

Smooth Muscle Hypertrophy/Hyperplasia. Remodeling of airway smooth muscle
(ASM), one of the main structural cells within the bronchi, is considered one of the
causes of airway obstruction due to ASM hypertrophy and hyperplasia. Moreover, the
migration of ASM cells toward the airway epithelium can also contribute to airway
remodeling [101]. In addition to the structural changes, ASM cells participate in the
inflammatory and remodeling process via the expression of cellular adhesion molecules,
receptors for cytokines, chemokines, and TLRs [102, 103]. Inflammatory mediators such
as TNF-a, IL-1b, and IFN-gamma have been shown to induce the expression of cellular
adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) in cultured ASM
cells, implicating ASM cells in regulating interactions with an array of inflammatory
cells including eosinophils and T lymphocytes [104, 105]. In healthy airways, ASM play
a significant role in regulating the respiratory airway tone and contractility. However,
thickening of the ASM layer is a prominent feature of the asthmatic airway [93, 106].
Studies reviewed by Gosens and Grainge suggest that bronchoconstriction resulting from
ASM contraction is sufficient to induce airway remodeling via processes triggered by
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mechanical forces, independent of inflammatory status [107]. ASM hypertrophy and
hyperplasia play a particular role in asthma symptoms in particular with regard to airway
hyperresponsiveness, with enhanced contraction being one of the main causes [108].

Airway Hyperresponsiveness
Airway hyperresponsiveness (AHR), a cardinal feature of asthma, is the
predisposition and increased ability of the airways to undergo bronchoconstriction, or
excessive narrowing, in response to a stimuli that would produce little to no effect in
apparently healthy individuals. Moreover, AHR is characterized by an increased airway
smooth muscle sensitivity to airway constrictor agonists such as histamine or
methacholine [109]. The mechanisms underlying AHR in asthma remain poorly
understood likely due to the numerous pathophysiological pathways associated with the
development of this condition. Genetic factors, airway inflammation and remodeling, as
well as enhanced airway smooth muscle contractility have been linked as to the
development of AHR [110]. Moreover, AHR is responsible for the recurrent episodes of
wheezing and shortness of breath associated with asthma, with increased AHR being
linked to more severe asthma [111]. The presence of AHR is associated commonly with
an increased decline in lung function and is most frequent in those individuals with a late
asthmatic response [112, 113]. Persistence of AHR can be short-lived or remain for up to
several months after exposure to a stimulant [113]. Clinically, the use of reductions in
spirometry parameters such as such as forced expiratory volume in one second (FEV1)
are used to assess changes in AHR and used as a tool to diagnose, classify disease
severity, and determine the management of asthma [114].
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1.3. Mitochondrial Structure and Function in the Normal and Pathological Lung
Mitochondria are individual entities, or organelles, ubiquitously found within
cells that arose from the fusion with another prokaryotic cell, referred to as the
endosymbiotic theory [115]. Mitochondria are considered individual entities because they
contain their own maternally inherited genome and have genetic continuity, but also
require the import of over 1,000 nuclear encoded proteins for proper function [116, 117].
Structurally, mitochondria contain two phospholipid membranes, the outer mitochondrial
membrane and the inner mitochondrial membrane, which form to distinct compartments
within the organelle, the mitochondrial matrix and the intermembrane space. Its main
function related to its structure is evident in the electron transport chain, where the
electrochemical gradient between the mitochondrial matrix and intermembrane space
allows cells to generate energy [118]. Moreover, mitochondria are also morphologically
complex and polymorphic undergoing fission and fusion in response to external insults
and metabolic cues [119, 120]. Furthermore, these double-membraned organelles are
dynamically organized and strategically trafficked within cells to support an array of vital
cellular functions [121].

1.3.1. Mitochondrial Function
Mitochondria are commonly referred to as the “powerhouses of the cell,” due to
their prominent role in energy production [122]. However, mitochondria have been
characterized also as a signaling organelle involved in numerous physiological functions
such as programmed cell death, innate immunity, autophagy, redox signaling, and
calcium homeostasis as well as metabolic reactions such as steroid hormone synthesis,
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lipid metabolism, and the interconversion of amino acids [123-125]. The main outputs
associated with mitochondria include adenosine triphosphate, reactive oxygen species,
and calcium. Mitochondria are key organelles in cells, as they are mainly involved in the
production and sequestering of these molecules.

Adenosine Triphosphate
Adenosine triphosphate (ATP) is the principal cellular energy source in aerobic
cells since its structure contains a high-energy chemical bond that releases free energy
when hydrolyzed and converted to adenosine diphosphate (ADP). ATP synthesis, or
oxidative phosphorylation, is dependent on the structural integrity of the mitochondrion,
particularly the mitochondrial matrix. The mitochondrial matrix contains enzymes
necessary for the tricarboxylic acid cycle and fatty acid beta-oxidation pathways and is
enclosed by an inner membrane that contains the four complexes (I-IV) of the electron
transport chain, ATP synthase (complex V), and specific metabolite carriers. During
oxidative phosphorylation, electrons are donated from reduced coenzymes such as
NADH and FADH2 and delivered to molecular oxygen via complexes I-IV. Complexes I,
III, and IV are redox pumps that establish a proton gradient across the inner
mitochondrial membrane and an electrochemical energy gradient that is used to transform
ADP into ATP by ATP synthase [126]. Moreover, in the lungs, mitochondria are found in
several populations of highly specialized cells to facilitate high energy-consuming
functions such as airway clearance via phagocytosis and ciliary movement, bronchial
gland secretion, constriction of airways, and production of pulmonary surfactant [127,
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128]. Although oxidative phosphorylation is a vital part of metabolism, it produces byproducts such as ROS.

Reactive Oxygen Species
Reactive oxygen species (ROS) are highly reactive chemicals, such as peroxides,
superoxide radical anions, and hydroxyl radicals, formed from oxygen, an ideal terminal
electron acceptor [129]. ROS are produced from various endogenous sources and
compartments of the cell including peroxisomes, phagocytic cells in the endoplasmic
reticulum, and as a by-product of inflammation [130]. However, mitochondria are the
major contributor of ROS, as they generate upwards of 90% of the total number of
cellular ROS [131]. As a result, mitochondria represent the key source of ROS
production in the majority of cell types. Nevertheless, at least ten sites within
mitochondria have been shown to play a role in ROS production. However, oxidative
phosphorylation and complexes I and III are thought to be the major contributors to
generation of unpaired electrons or radicals [132-134]. It has been proposed that
mitochondria regulate their activity to maintain a membrane potential that balances ATP
synthesis against ROS production, as oxidants can uncouple proteins that reduce
membrane potential [135]. To counteract these effects, cells contain multiple antioxidant
enzymes such as superoxide dismutase, catalase, and peroxiredoxins

[136].

Mitochondrial ROS are implicated in cell function, as they participate in multiple
networks that control the cell cycle, stress responses, energy metabolism, and redox
balance as well as a variety of degenerative processes [137].
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Calcium
Calcium ions play a crucial and universal role as a second messenger [138].
Calcium is a versatile signaling molecule with an array of physiological functions
including muscle contraction, neuronal excitability, cell proliferation, and cell migration.
Moreover, calcium is an important regulator of mitochondrial function [139]. Within the
mitochondrion, calcium acts at several levels to stimulate oxidative phosphorylation
through the allosteric activation of various calcium-sensitive dehydrogenases and the
stimulation of ATP synthase [140, 141]. Consequently, mitochondrial ATP outputs can
be modified through calcium buffering to meet the cellular energy demands [142].
Likewise, calcium influx within mitochondria can occur when there is an increase in both
the endoplasmic reticulum calcium release and cytosolic calcium concentrations. The
mitochondrial membrane aids in regulating calcium concentrations by functioning as a
reservoir and a buffer depending on local cellular conditions [143]. An elevation of
mitochondrial matrix calcium results in the upregulation of the respiratory chain
machinery, resulting in higher ATP outputs. Additionally, mitochondrial matrix overload
can lead to changes in the mitochondrial membrane potential and increased ROS,
triggering the permeability transition pore, and cytochrome c release, ultimately leading
to apoptosis [144]. Overall, calcium is a positive global effector of mitochondrial
function, with a delicate balance between the positive and negative effects of calcium.

1.3.2. Mitochondrial Dynamics and Trafficking
Mitochondria are highly dynamic organelles that can change in size, shape, and
distribution [122, 145]. Mitochondria undergo coordinated cycles of fission and fusion,
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termed ‘mitochondrial dynamics,’ to adapt morphologically. Mitochondria are trafficked
on microtubule tracks for spatial and temporal control of cellular processes such as the
cell cycle, immunity, apoptosis, mitochondrial biogenesis, mitochondrial quality control
(mitophagy) and cell migration [146, 147]. Mitochondrial dynamics are mediated by
several large GTPases and their combined effects lead to the formation of the fluid
mitochondrial networks in many cell types. Imbalances in mitochondrial dynamics leads
to structural changes and dysfunction. It is believed that mitochondrial dynamics allows
the appropriate distribution of mitochondrial metabolites to localized cytosolic regions.

Mitochondria Fusion
Mitochondrial fusion is the physical merging of the outer and inner mitochondrial
membranes of two distinct mitochondria. In mammals, mitochondrial fusion is tightly
regulated by three dynamin-related GTPases proteins namely mitofusin 1 (Mfn1),
mitofusin 2 (Mfn2), and optic atrophy 1 (OPA1) [148]. Mfn1 and Mfn2 reside in the
outer mitochondrial membrane, while OPA1 localizes to the inner mitochondrial
membrane. Because mitochondria are double-membraned organelles, the activation of
these GTPases leads to the three-step mitochondrial fusion process. To initiate
mitochondrial fusion, mitofusins tether to adjacent copies of themselves on nearby
mitochondria and form a ring structure around the contact point between the outer
membranes [149]. Subsequent GTP hydrolysis triggers the outer membrane fusion event,
followed by fusion of the inner membranes by OPA1 rendering a new mitochondrial
network [146]. Alterations in expression of these proteins can lead to distinct
mitochondrial morphologies. Overexpression of Mfn1 and Mfn2 leads to perinuclear
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mitochondrial clustering, while underexpression of Mfn1 and Mfn2 leads to
mitochondrial

fragmentation

[150].

Likewise,

knockdown

of

OPA1

induces

mitochondrial fragmentation and overexpression of OPA1 leads to mitochondrial
elongation [151, 152]. Fusion is necessary to help alleviate mitochondrial stress by
mixing the contents of partially damaged mitochondria with healthy mitochondria to
prevent the loss of essential components [153].

Mitochondrial Fission
Mitochondrial fission is the process where mitochondria divide into two distinct
organelles, an important process for remodeling and rearrangement of mitochondrial
networks during development [154], apoptosis [155], acute organ injury [156], as well as
the segregation of mitochondria during cell division [157]. The large GTPase dynaminrelated protein 1 (Drp1) is a central player in mitochondrial fission. Although Drp1 is not
localized to the mitochondrial membrane and described as being mostly a cytoplasmic
protein, it can associate with the mitochondrial membrane via interactions with
mitochondrial receptors [158-161]. Drp1-mediated fission is an intricate process
involving the translocation of Drp1 to the mitochondrial outer membrane, followed by its
high-order assembly, GTP hydrolysis, and its disassembly [159]. At the mitochondrial
outer membrane, Drp1 binds to receptors and forms a functional complex that is
transported from the cytoplasm to the fission site [148]. Moreover, the transfer of calcium
from the endoplasmic reticulum into the mitochondrion results in the recruitment of Drp1
to the mitochondrial surface [162]. Reduced Drp1 activity, mainly through impaired
calcium signaling and intercellular communication, is seen in aged mice leading to
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defective organelle morphogenesis in oocytes [163]. Genetic loss of Drp1 leads to
pronounced mitochondrial elongation in multiple cell lines and animal models [154, 164].
Additionally, downregulated or inactivated Drp1 can lead to genomic instability,
autophagy escape, reduction of invasion and migration, and reduction of cell viability
[165]. Conversely, Drp1 overexpression does not lead to enhanced mitochondrial fission
since Drp1 activity relies on its activation by various post-translational modifications, as
well as the translocation from the cytosol to mitochondria [166]. Upregulation and
activation of Drp1 has been associated with increased cell proliferation, cell invasion and
migration, and mitophagy [165]. Mitochondrial fission is required for mitophagy as it
enables the separation of depolarized mitochondria from the mitochondrial network,
ultimately allowing the engulfment of autophagosomes [167, 168].

Mitochondrial Trafficking
Subcellular mitochondrial positioning has emerged as a critical component for an
array of cellular processes including cell division[167], migration [169, 170] , signaling
[171], and PINK1/Parkin-dependent mitophagy pathways [172]. Calcium-binding
mitochondrial Rho 1 and 2 (Miro1/2) GTPases are key regulators of mitochondrial
transport along microtubules [173]. Miro1 and Miro2 are C-terminally-anchored proteins
in the outer mitochondrial membrane with two GTPase domains and two calcium binding
embryonic fibroblast (EF) hand motifs facing the cytoplasm [174-178]. Evidence
suggests that Miro proteins also function as mitochondrial calcium sensors via the EF
hand motifs [179, 180]. Moreover, Miro proteins are the only known surface receptors
that tether mitochondria to the trafficking adapter proteins 1 (TRAK1) and TRAK2 that
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associate with the microtubule-associated molecular motors kinesin and dynein for longrange mitochondrial transport [174-176, 181-183] (Figure 3). Miro1 also associates with
the actin motor protein myosin-19 for shorter distance movements [184]. A study using
Miro1/2 protein double knockout cell lines suggest that TRAK proteins localize to
mitochondria in the complete absence of Miro proteins, while myosin-19 mitochondrial
transport is dependent on Miro1 proteins [173]. Moreover, Miro1 knockout, but not
Miro2, in cells show that mitochondria localize and concentrate in the perinuclear region
of cells [173, 185]. Miro1/2 protein double knockout in cells results in a more
accentuated mitochondrial perinuclear accumulation when compared to Miro1 knockout
cells [173]. However, it has been shown that the number of microtubule-dependent
mitochondrial trafficking events is significantly reduced in Miro1 knockout cells when
compared to the unaltered trafficking events in Miro2 knockouts in cells [173]. Miro1
and Miro2 are roughly 60% identical and have non-redundant roles in regulating
mitochondrial trafficking and distribution, with Miro1 being the key adaptor protein in
regulating subcellular microtubule-dependent mitochondrial trafficking [174, 175].
Defects in Miro1-mediated mitochondrial trafficking has been implicated and thoroughly
described in cancer [186, 187], metabolic conditions [188, 189], and especially
neurological disorders such as Parkinson’s disease [172, 190-194], as it can disrupt
membrane dynamics and energy levels in the distant cortical cytoskeleton.
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Figure 3. Miro1 is the Primary Adaptor Protein for Microtubule-Dependent Trafficking

1.3.3. Mitochondrial Dysfunction in Asthma
In asthma, the airway epithelium is frequently injured by aeroallergens,
environmental pollutants, and oxidants, leading to inflammation via the secretion of proinflammatory molecules and immune cells. This response promotes oxidative stress in the
airways through the release of various ROS including superoxide anions, hydroxyl
radicals, hydrogen peroxide, and nitric oxide. ROS can damage the surrounding airway
epithelial cells and amplify the associated inflammation leading to structural changes
such as thickened basement membranes, shedding of the surface epithelium, smooth
muscle

cell

hypertrophy/hyperplasia,

goblet

cell

hyperplasia/metaplasia,

and

angiogenesis surrounding the airways [14]. These structural changes alter airway
function, leading to the signs and symptoms associated with asthma. Moreover, following
cellular stress or injury, mitochondrial membranes can be damaged and become
dysfunctional. Mitochondrial dysfunction is characterized by ROS accumulation, loss of
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membrane potential, mitochondrial calcium overload, mitochondrial DNA (mtDNA)
mutation or release, and mitophagy dysregulation [195].
The literature suggests that mitochondrial dysfunction has been implicated in the
pathogenesis of asthma. A murine model study of ovalbumin-induced asthma by Jaffer et
al. showed that mtROS, TGF-β, and collagen deposition are increased when compared to
mice treated with saline. Moreover, these authors also show that Mito-TEMPO, a
mitochondria-targeted antioxidant, significantly decreases mtROS in ovalbuminchallenged mice. Human airway epithelial cells from the same study treated with IL-13
showed an increase in mtROS and collagen expression, which were also diminished by
the Mito-TEMPO treatment [196]. Other studies suggest that antioxidant enzymes are
decreased in the peripheral tissue of asthmatic adult patients when compared to control
subjects, showing that oxidative stress and mitochondrial dysfunction are present in
asthmatics [197-201]. Other studies have shown increased mtROS in the venous blood of
severe asthmatics when compared to apparently healthy individuals [202]. Furthermore,
polymorphisms in mitochondrial encoded genes associated with mtROS production have
been found in asthmatic children, indicating a genetic predisposition to increased asthma
risk [203]. Other studies have shown that increased production of mtROS can lead to loss
of membrane potential and ATP depletion, leading to the initiation of cytochrome c and
caspase-3 apoptotic pathways [204]. Regarding mitochondrial membrane potential
alterations, another study suggests that fibroblasts from severe asthmatics have reduced
membrane potential with reduced membrane activity, as well as the increased mitophagy
as suggested by an increase in PINK1 and Parkin [205]. Evidence also suggests that
mitochondrial mass and oxygen consumption are higher in the bronchial smooth muscle
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of those with asthma. This finding has been linked to an enhanced extracellular calcium
influx and mitochondrial biogenesis. These changes might lead to the proliferation of
bronchial smooth muscle cells and remodeling changes within the airway [206]. Another
study shows that a mitochondrial calcium uniporter deficiency suppresses mitochondrial
calcium uptake (MCU) and ROS production. Suppression of the MCU also maintained
the mitochondrial membrane potential and had protective effects against apoptosis in
response to IL-13 [207]. The literature also shows that allergen-induced ROS generation
leads to the activation of calcium/calmodulin-dependent kinase II (CaMKII), which plays
a role in mitophagy regulation. Activation of this kinase can result in airway
hyperresponsiveness, ROS generation, and Th2 inflammatory responses in the lung.
Inhibition of CaMKII reduces allergen-induced mitophagy, mitochondrial dysfunction,
and cytokine production in the airway epithelium. These changes reduce the subsequent
airway hyperresponsiveness and inflammation that leads to the pathogenesis of asthma
[208]. Finally, an in vivo model of asthma using wild-type and Parkin deficient mice
showed that inoculation with IL-13 leads to increased numbers of neutrophils and
eosinophils in the BALF of wild-type mice when compared to Parkin deficient mice. IL13 also enhanced mtDNA release and chemokine levels in the BALF of wild-type mice
when compared to Parkin deficient mice. Similarly, an in vitro experiment from the same
study demonstrated that Parkin deficient human bronchial epithelial cells inhibit mtDNA
release when exposed to IL-13. Data from this study suggest a link between mitophagy,
mtDNA, and inflammation in the development and progression of asthma [209].
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1.4. Miro1-mediated Mitochondrial Positioning and Chronic Inflammatory Lung
Conditions
Mitochondria are the primary source of cellular ATP and produce substantial
amounts of ROS, which play a significant role in the lung epithelium in response to an
external stimuli [14, 210, 211]. The fluid reorganization of mitochondrial networks
enables the positioning of functional mitochondria to sites requiring mitochondrial
metabolites [121]. Mitochondria are transported and strategically repositioned throughout
the cell by the microtubule-associated molecular motors kinesin and dynein and function
as subcellular barriers that allow the compartmentalization of signaling and amplification
of responses [212-214]. The attachment of mitochondria to these molecular motors is
primarily mediated by a protein complex that includes TRAK1/2 and Miro1/2 [174-176,
181-183]. In polarized lung epithelial cells, mitochondria localize at the apical and
basolateral poles of cells, which allows the compartmentalization of calcium signaling
following ipsilateral receptor activation in the plasma membrane [215, 216].
Furthermore, the uncoupling of mitochondrial oxidative phosphorylation with FCCP
prevents the compartmentalization of calcium signaling in polarized lung epithelial cells
[215]. Our laboratory has shown that deletion of Miro1 in mouse embryonic fibroblasts
confines intracellular ATP and ROS gradients to the perinuclear space and disrupts
membrane reorganization and redox dependent signaling [217, 218]. The mechanism
regulating mitochondrial positioning in the lung epithelium remains unknown.
Sundar et al. [219] looked at the role of Miro1 in cigarette smoke extract-induced
mitochondrial dysfunction in vitro. This study showed that cigarette smoke extract
treatment leads to mitochondrial dysfunction associated with increased concentrations of
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mtROS, increased mitochondrial mass, and reduced membrane potential in primary lung
epithelial cells. Moreover, cigarette smoke extract exposure altered the abundance of
oxidative phosphorylation protein complexes, which was correlated with changes in the
mitochondrial respiratory chain as evidenced by decreased basal and maximal respiration,
diminished ATP production, and reduced spare capacity. Furthermore, chronic cigarette
smoke extract exposure in lung epithelial cells showed an increase in mitochondrial
fragmentation and perinuclear clustering around the nucleus. These structural changes
were linked to increased Drp1 and reduced Mfn2 protein abundances. Cigarette smoke
extract treatment significantly reduced Miro1 and PINK1 protein levels in primary lung
epithelial cells.
An in vivo study from the same laboratory used an epithelial-specific partial and
complete Miro1 knockout mouse model to assess the effects of acute and chronic
exposure to cigarette smoke extract. Sharma et al. [220] found that cigarette exposure in
mice with Miro1 ablation from CC10 positive cells leads to increased expression of proinflammatory and inflammatory mediators in the BALF. Moreover, total cell counts,
macrophages count and neutrophil counts were also significantly elevated in the BALF.
Histopathological changes observed with Miro1 deletion included foamy macrophages
and epithelial hyperplasia. Although some structural changes were noted, no changes in
the lung mechanics were appreciated. Findings from both studies strengthen the concept
that Miro1 is a key player in exerting the inflammatory responses due to cigarette smoke
in the lungs, which is in part mediated by cigarette smoke-induced mitochondrial
dysfunction and impaired quality control.
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CHAPTER 2: DISRUPTION OF MITOCHONDRIAL TRAFFICKING IN LUNG
EPITHELIAL CELLS POTENTIATES ALLERGIC ASTHMA PHENOTYPES
2.1. Introduction
Allergic asthma is a complex, chronic inflammatory condition of the small
airways that affects as many as 300 million people of all ages worldwide, including 25
million Americans (about 8.5% of the United States’ population), and accounts for
approximately 400,000 million [1-3]. Generally, a combination of environmental and
genetic factors can cause allergic asthma [4, 5]. However, allergen exposure is the single
most important cause of allergic asthma and the main driver of acute episodes, or
“attacks,” of airway inflammation, increased mucus production, and obstruction and
narrowing of the airways [221]. These disruptive changes to the airway epithelium, the
first line of protection against external insults and pathogens, can lead to some of the
classical symptoms associated with allergic asthma such as chest tightness, difficulty
breathing, wheezing, and persistent coughing [7]. In allergic asthma, the airway
epithelium is frequently injured by allergens, leading to the secretion of pro-inflammatory
cytokines and chemokines, as well as the recruitment and activation of innate and
adaptive immune cells [222]. Chronic activation of these pro-inflammatory molecules
potentiates structural changes in the airways such as thickened basement membranes,
shedding of the surface epithelium, subepithelial fibrosis, mucus hyperplasia and
metaplasia, and increased angiogenesis surrounding the airways [77]. These structural
changes to the airways lead to functional changes, making it difficult to breathe.
Currently, there is no cure for allergic asthma. Avoidance of triggers and the use
of bronchodilators and anti-inflammatory drugs such as inhaled rapid-acting β-2
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adrenergic agonists and oral corticosteroids are commonly recommended for the
management of symptoms. However, these current treatment options fail in upwards of
10% of patients or have serious side effects [13, 14], making it necessary to study novel
molecular targets to better understand the pathophysiological nature of allergic asthma
and to explore alternate therapeutic options.
Ample evidence suggests that mitochondria play a key role in lung health and
pathophysiology [223-226]. Mitochondria, the “powerhouses of the cell,” are the main
producers of adenosine triphosphate (ATP). Moreover, mitochondria are a primary source
of reactive oxygen species (ROS), and can actively buffer calcium (Ca2+) [144].
Following cellular stress, mitochondrial membranes can be damaged and may become
dysfunctional. Mitochondrial dysfunction is characterized by ROS accumulation, loss of
membrane potential, mitochondrial Ca2+ overload, mitochondrial DNA mutation or
release, and mitophagy dysregulation [195]. Increased production of ROS has been
implicated in the development of chronic inflammatory lung conditions such as asthma
[14, 210]. As a result, these double-membraned organelles can change in size, shape, and
distribution depending on intracellular mitochondrial metabolite demands [121, 122].
Within the cell, mitochondria are transported on the microtubule-associated molecular
motors kinesin and dynein [212-214], and tethered to these motors by a protein complex
composed of trafficking kinesin protein 1 and 2 (TRAK1/2) and Mitochondrial Rho
GTPase 1 and 2 (Miro1/2) [174-176, 181-183]. Miro1 shares approximately 60%
homology with Miro2, but evidence shows Miro1 is the primary adaptor protein required
for the subcellular positioning of mitochondria within differentiated cells [173, 185]. The
dynamic reorganization of mitochondrial networks is important in highly active cells,
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such as airway epithelial cells, due to their increased need in energy to maintain the
functionality of the airways. Evidence suggests that mitochondria are positioned at the
apical and basolateral poles of polarized airway epithelial cells to allow calcium signaling
[215], and provide energy for mucus to be secreted and cleared [227-230], which
becomes critical during high energy demand events such as stress or injury. Recent in
vitro and in vivo models of COPD suggest that Miro1 plays a contributing role to this
pathology [219, 220]. Until now, the role of Miro1-mediated mitochondrial positioning in
the context of allergic asthma remained unexplored.
Herein, we have developed a novel mouse model to study Miro1 biology in the
context of allergic asthma, where we hypothesize that epithelial-deletion of Miro1 leads
to exacerbated inflammatory responses following chronic allergen exposure (Figure 4).
We find that epithelial ablation of Miro1 following chronic exposure to house dust mite
(HDM) leads to significant changes in tissue architecture and organization, as well as
changes in lymphocyte infiltration and airway hyperresponsiveness.
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Figure 4. Schematic Representation of Miro1 Expression Leading to Appropriate or
Exacerbated Airway Responses Following Allergen Challenge
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2.2. Materials and Methods
2.2.1. Study Approval
All mouse studies were approved by the Institutional Animal Care and Use
Committee of the University of Vermont, Burlington, VT, USA under protocol number
PROTO202000216.

2.2.2. House Dust Mite
HDM (XPB70D3A2.5, Stallergenes Greer, Lenoir, NC, USA) was suspended in
Phosphate Buffered Saline (PBS). HDM concentration was determined by total protein
concentration in HDM vial.

2.2.3. Epithelial Tissue-Specific Transgenic Mice
To achieve conditional airway epithelial specific deletion, C57B/L6 mice
containing floxed Miro1 alleles (Miro1flx/flx) were crossed with double transgenic mice
containing a Clara Cell secretory protein (CCSP) promoter fused to a reverse tetracycline
trans activator (rTetA) and a Tet operon fused to Cre recombinase (TetOP-Cre), termed
CCSP-rTetA/TetOP-Cre,

to

generate

triple

transgenic

(CCSP-rTetA/TetOP-

Cre/Miro1flx/flx) mice, referred to as ∆Epi-Miro1. Mice containing the three gene inserts
were used to conditionally delete Miro1 in CCSP positive airway epithelial cells upon
exposure to doxycycline-containing food for 7 days. Littermates missing one of the three
gene inserts (CCSP-rtTA, TetOP-Cre, or Miro1flx/flx) also on the doxycycline-containing
food were used as control mice.
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2.2.4. Experimental Design
An established model of allergic asthma was used for all experiments. In this
model, 25 µg of HDM or PBS was administered to control and ∆Epi-Miro1 mice via
nasopharyngeal aspiration. Mice were sensitized to the allergen 7 days after the start of
the doxycycline-containing food. In this chronic model of allergen challenge, the allergic
response in mice was boosted 7 days after sensitization and challenged for five
consecutive days 14 days after sensitization with HDM or PBS. Mice were sacrificed 24
hours following the last allergen challenge.

2.2.5. Tissue Processing
Following euthanization, left lung lobe tissue was collected, inflated, and fixed in
4% paraformaldehyde for 24-48 hours at 4o C. Formaldehyde-fixed lung tissue was sent
to the University of Vermont Medical Center for paraffin embedding. Tissue blocks were
serially sectioned at a 5 μm thickness using a Leica 2030 manual paraffin microtome
(Microscopy Imaging Center, University of Vermont). Tissue sections were mounted
onto glass slides and dried in an oven at 52o C for 60 minutes. De-paraffinization and
tissue rehydration for all staining procedures was achieved by immersing the glass slides
through the following solutions: three 15 minute xylene washes, two 5 minute washes for
100% ethanol and 95% ethanol, and a 5 minute wash for 70% ethanol, 50% ethanol, and
dH2O.
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2.2.6. Mucus Metaplasia Quantification
Periodic Acid Schiff (PAS) staining was conducted to assess mucus metaplasia.
Lung tissue slides were immersed in 0.5% periodic acid for 10 minutes, followed by three
5 minute rinses in dH2O, and 30 minutes in Schiff reagent. Next, two 1 minute washes in
0.55% potassium metabisulfite, followed by a 10 minute rinse under running water.
Tissue was counterstained by immersing slides for 10 minutes in hematoxylin, rinsed
under running water for 5 minutes, and 2 dips in 0.5% lithium carbonate. Images were
captured at 20x magnification by Leica VERSA8 whole slide imager (Microscopy
Imaging Center, University of Vermont). Mucus metaplasia was measured in the airways
by measuring positive PAS stained area using the Positive Pixel Count algorithm of Leica
Aperio ImageScope Software (Aperio Technologies, San Diego, CA, USA). The Positive
Pixel Count algorithm outputs used to determine the positive PAS stained area were
number of strong positive pixels normalized to lung tissue area.

2.2.7. Remodeling Quantification
Masson’s trichrome staining was conducted to assess remodeling changes. Lung
tissue slides were immersed for 1 hour in Bouin’s solution at 56 o C and cooled to room
temperature. Tissue was rinsed under running water until stain disappeared. Tissue was
stained for 10 minutes in Wiegert hematoxylin and washed under running water for 10
minutes. Next, tissue was stained for 2 minutes in Biebrich Scarlet-Acid Fuchsin
solution, followed by a rinse in dH2O, and then immersed for 10-15 minutes in a
phosphomolybdic/phosphotungstic acid solution. The last stain was 5 minutes in aniline
blue, followed by a rinse in dH2O, and 3-5 minutes in a 1% acetic acid solution. Nuclei
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were stained in black; cytoplasm, keratin, and muscle fibers were stained in red; and
collagen was stained in blue. Images were captured at 20x magnification by Leica
VERSA8 whole slide imager (Microscopy Imaging Center, University of Vermont).
Representative images of the small airways were captured for each experimental group.
Images were de-identified and blindly scored using an arbitrary unit (A.U.) scale ranging
from 1-8 by ~6 separate individuals. The arbitrary unit scoring scale assessed changes in
remodeling including collagen deposition, immune cell infiltration, epithelial layer
thickening, and alveolar space changes. Lower scores signified little to no remodeling
changes and higher scores signified increased remodeling changes. Mean A.U. scores per
evaluator were obtained and these were averaged per experimental condition.

2.2.8. α-Smooth Muscle Actin Immunohistochemistry and Quantification
Immunohistochemical staining was used to determine changes in airway smooth
muscle levels. Lung antigen retrieval was achieved by submersing slides in a DAKO
antigen retrieval solution for 20 minutes at 95o C, slides were then allowed to cool down
for 20 minutes at room temperature, and rinsed in three 5 minute PBS washes. Lung
tissue slides were blocked in a 10% H2O2 in methanol solution for 15 minutes, followed
by seven 5 minute PBS washes. A 2.5% normal goat serum protein block (Vector
Laboratories) was put on the slides for 15 minutes, followed by overnight incubation of
primary α-smooth muscle actin antibody (Abcam, ab5694) diluted to a 1:2000
concentration in PBS at 4o C. Following overnight incubation, slides were rinsed in seven
5 minute PBS washes and a ImmPRESS polymer reagent (Vector Laboratories) was put
on the tissue for 30 minutes at room temperature. Tissue was rinsed in seven 5 minute
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PBS washes and exposed to a diaminobenzidine (DAB) peroxidase solution (Vector
Laboratories) for immunohistochemical staining. Tissue was rinsed in dH2O and
counterstained with hematoxylin and ammonium hydroxide.

2.2.9. Airway Hyperresponsiveness Assessment
Mice were anesthetized using sodium pentobarbital (90 mg/kg) via intraperitoneal
injection and tracheotomized using 18-guage cannulas. Mice were mechanically
ventilated at a rate of 200 breaths/minute using FlexiVent computer controlled smallanimal ventilator (SCRIREQ, Montreal, QC, Canada). Airway hyperresponsiveness
parameters such as Newtonian resistance (Rn), tissue dampening (G), and tissue elastance
(H) were measured in the mice after exposure to increasing concentrations (12.5 mg/ml,
25 mg/ml, and 50 mg/ml) of aerosolized methacholine. Measurement of lung mechanics
presented are the average of three peak measurements.

2.2.10. Bronchoalveolar Lavage Fluid Collection and Processing
Bronchoalveolar lavage fluid (BALF) was collected by washing the airways with
1 mL of sterile PBS. Cells were isolated via centrifugation and total cell counts were
determined using a hemocytometer (3110, Hausser Scientific, Horsham, PA, USA).
Cytopsins were conducted and cells were stained using Hema3 stain reagents (Fisher
Scientific, Waltham, MA, USA) to obtain differential cell counts. A minimum of 300
cells were counted to determine differential cell counts.
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2.2.11. ELISAs
Right side lung lobes were flash frozen immediately after harvest and crushed to
make lysates in buffer containing 137 mM Tris HCL (pH 8.0), 130 mM NaCl, and 1%
NP-40. Samples were normalized to total lung protein and used to assess expression
levels of IL-6, IL-33, CCL20, Eotaxin-1 (DuoSet ELISA Kits, R&D Systems,
Minneapolis, MN, USA), IL-4, IL-13 (eBioscience Kits, Thermo Fisher Scientific,
Waltham, MA, USA), and MUC5AC (Novus Biologicals, Littleton, CO, USA) per
manufacturer’s instructions.

2.2.12. Caspase Assay
25 μg of tissue lysates was diluted to 25 µL in dH2O. Following dilution, tissue
lysates were incubated with 25 µL Caspase-Glo 3/7 assay reagent (Promega) in an
opaque plate in a dark room for 30 minutes at room temperature. Total luminescence was
measured using a Synergy HTX plate reader (Biotek) and values were recorded as
relative activity.

2.2.13. Statistical Analyses
Normal data were analyzed by one-way ANOVA and Tukey’s multiple
comparisons posttest. A p-value <0.05 was considered significant. Data were averaged
and expressed as the mean ± SEM.
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2.3. Results
2.3.1. Conditional Deletion of Miro1 In Vivo Enhances the Pro-Inflammatory
Response following Chronic HDM Exposure in a Mouse Model of Allergic Airway
Disease
To assess changes in the epithelial pro-inflammatory response to HDM following
the conditional deletion of Miro1, we generated a CC10-rTetA/TetOP-Cre/Miro1flx/flx
mouse model to delete Miro1 in CCSP positive lung epithelial cells in the presence of
doxycycline (Figure 5). Mice were given doxycycline-containing chow 7 days before the
start of the chronic allergic airway disease protocol. The doxycycline diet was maintained
until the end of the sensitization exposure and chronic allergen challenges. Mice were
sensitized intranasally to HDM on days 0 and 7 with 25 µg of HDM, followed by five
consecutive day challenges with 25 µg of the allergen or the phosphate buffered saline
(PBS) control. Mice were sacrificed 24 hours after the last allergen challenge to assess
the role of Miro1 in the allergic airway response (Figure 6). BALF was analyzed for
immune cell infiltration into the lung. This analysis revealed no statistically significant
differences in the number of total cell infiltrates, as well as select immune cells such as
macrophages, eosinophils, and neutrophils among control and ΔEpi-Miro1 mice exposed
to HDM. However, a significant increase in the number of lymphocytes in the lungs of
ΔEpi-Miro1 mice challenged with HDM was observed when compared to control mice
exposed to HDM (Figure 7). Moreover, whole lung tissue lysates were analyzed for
several epithelial-secreted pro-inflammatory cytokines, chemokines, and Th2 adaptive
cytokines via enzyme-linked immunosorbent assay (ELISA). There were no statistically
significant differences observed in the production of the pro-inflammatory cytokines IL-6
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and IL-33 or the Th2-specific cytokines IL-4 and IL-13 between the ΔEpi-Miro1 mice
challenged with HDM, when compared to the HDM-challenged control mice.
Conversely, ΔEpi-Miro1 mice challenged with HDM expressed a statistically significant
increase in the levels of the chemokines CCL20 and Eotaxin (Figure 8). These results are
suggestive of a potential role for Miro1-mediated mitochondrial positioning in the
regulation of specific epithelial pro-inflammatory signaling.

Figure 5. Experimental mouse model using CCSP-rTetA/TetO-Cre/Miro1flx/flx mice to
achieve epithelial deletion of Miro1 following doxycycline exposure.
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Figure 6. Deletion and HDM exposure protocol.

ΔEpi-Miro1 mice and control mice were given a doxycycline-containing diet 7 days prior
to the start of experiments. ΔEpi Miro1 mice were sensitized to HDM on day 7, boosted
on day 14, and serially challenged for 5 consecutive days starting on day 21.
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Figure 7. Conditional deletion of Miro1 from airway epithelial cells enhances
lymphocyte levels in the mouse lungs following chronic exposure to HDM.

(A) Total inflammatory cells present in the BALF, n = 5 – 6 mice per group from one
experiment. (B-E) Inflammatory cell-specific totals in the BALF, n = 5 – 6 mice per
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group from one experiment. (A-E) * p-value < 0.05 vs. corresponding PBS group, # pvalue < 0.05 vs. Control HDM group. Error bars represent mean ± SEM. Data collected
in collaboration with Sierra Bruno, PhD from the Anathy Lab at the University of
Vermont.

Figure 8. Conditional deletion of Miro1 from airway epithelial cells enhances chemokine
expression in mouse lungs following chronic exposure to HDM.
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(A) ELISAs of pro-inflammatory cytokines in the whole lung lysates, n = 5 – 6 mice per
group from one experiment. (B) ELISAs of pro-inflammatory chemokines in the whole
lung lysates, n = 5 – 6 mice per group from one experiment. (C) ELISAs of Th2 adaptive
cytokines in the whole lung lysates, n = 5 – 6 mice per group from one experiment. (A-C)
* p-value < 0.05 vs. corresponding PBS group, # p-value < 0.05 vs. Control HDM group.
Error bars represent mean ± SEM. Data collected in collaboration with Sierra Bruno, PhD
from the Anathy Lab at the University of Vermont.

2.3.2. Conditional Deletion of Miro1 In Vivo Augments Mucus Metaplasia
Mucus metaplasia is a hallmark of allergen-induced asthma and an indicator of
severity [231-233]. Thus, we examined mucin secretion into the BALF in the lungs after
Miro1 deletion from the airway epithelium via ELISA. There were no statistically
significant differences in the MUC5AC secretion between ∆Epi-Miro1 mice and control
mice exposed to HDM in the BALF (Figure 9A). To assess mucus levels histologically,
lung tissue was stained using the PAS stain. Intriguingly, mucus staining was
significantly increased in the airways of ∆Epi-Miro1 challenged with HDM when
compared to the HDM-challenged control mice (Figure 9B). These data suggest that
epithelial Miro1 may regulate mucin secretions, further suppressing severity of the
allergic response to HDM.

43

Figure 9. Conditional deletion of Miro1 from airway epithelial cells enhances mucus
metaplasia following HDM exposure.

(A) ELISA of MUC5AC in the BALF, n = 5 – 6 mice per group from one experiment.
(B) Quantification of PAS staining, n = 3 – 6 mice per group from one experiment. (C)
Representative images of PAS staining in lung tissue sections from one experiment. (AB) One-way ANOVA, * p-value < 0.05 vs. corresponding PBS group, # p-value < 0.05
vs. Control HDM group. Error bars represent mean ± SEM. (C) Scale bars are 200 µm.
MUC5AC data collected in collaboration with Sierra Bruno, PhD from the Anathy Lab at
the University of Vermont.

44

2.3.3. Conditional Deletion of Miro1 In Vivo Enhances Tissue Remodeling
To assess airway tissue remodeling, changes such as collagen deposition, immune
cell infiltration, epithelial layer thickening, and alveolar space size in the lung tissue were
examined using the Masson’s trichrome tissue stain. There were marked remodeling
changes observed, as indicated by higher AU scores, in the lung tissue of ∆EpiMiro1 mice challenged with HDM, when compared to control mice challenged with
HDM (Figure 10). These data suggest that Miro1 might help prevent severe remodeling
changes in the airway epithelium following allergen exposure.

Figure 10. Conditional deletion of Miro1 from airway epithelial cells enhances tissue
remodeling following HDM exposure.

(A) Representative images of Masson’s trichrome staining in lung tissue sections, n = 3 –
6 from one experiment. Scale bars are 200 µm. (B) Quantification of Masson’s trichrome
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staining. The arbitrary unit scoring scale assessed changes in remodeling including
collagen deposition, immune cell infiltration, epithelial layer thickening, and alveolar
space changes. Lower scores signified little to no remodeling changes and higher scores
signified increased remodeling changes. Error bars represent mean ± SEM. One-way
ANOVA, * p-value < 0.05 vs. corresponding PBS group, # p-value < 0.05 vs. Control
HDM group.

2.3.4. Conditional Deletion of Miro1 In Vivo Augments Airway Smooth Muscle
Levels
To assess airway smooth muscle changes, lung tissue was stained for α-smooth
muscle actin via immunohistochemistry. Although there were no statistically significant
differences between α-smooth muscle actin levels in the lung tissue of ∆Epi-Miro1 mice
and control mice exposed to HDM, a marked phenotypic difference can be seen in the
lung tissue of ∆Epi-Miro1 mice and control mice exposed to HDM (Figure 11).
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Figure 11. Conditional deletion of Miro1 from airway epithelial cells increases smooth
muscle levels following HDM exposure.

(A) Representative images of α-smooth muscle actin immunohistochemical staining in
lung tissue sections, n = 2 mice per group from one experiment. Scale bars are 200 µm.
(B) Quantification of α-smooth muscle actin staining. Data points shown are the mean of
n = 79 – 111 airways from each mice per group. Error bars represent mean ± SEM. Oneway ANOVA, * p-value < 0.05 vs. corresponding PBS group.

2.3.5. Conditional Deletion of Miro1 In Vivo Enhances Epithelial Apoptosis
Activation of the apoptosis regulator, Caspase-3, in the mouse lung tissue was
examined using a Caspase Glo assay. A statistically significant increase in the activity of
caspases in tissue lysates of ∆Epi-Miro1 mice exposed to HDM mice was observed, when
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compared to control mice exposed to HDM (Figure 12). These data suggest an increase
in apoptosis in the airway epithelium. These data indicate a worsened allergic airway
response to HDM after conditional Miro1 deletion with enhanced epithelial cell death.

Figure 12. Conditional deletion of Miro1 from airway epithelial cells enhances epithelial
cell death following HDM exposure.

(A) Luminescence activity assay of Caspase 3 and 7 (Caspase Glo Assay) in whole lung
lysates, n = 4 – 6 mice per group from one experiment. One-way ANOVA, * p-value <
0.05 vs. corresponding PBS group, # p-value vs. Control HDM group. Error bars
represent mean ± SEM. Data collected in collaboration with Sierra Bruno, PhD from the
Anathy Lab at the University of Vermont.
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2.3.6. Conditional Deletion of Miro1 In Vivo Enhances Airway Hyperresponsiveness
following Methacholine Challenge
Methacholine-induced airway hyperresponsiveness in an established chronic
HDM-induced allergic airway disease model was assessed. ∆Epi-Miro1 mice exposed to
both PBS and HDM show slightly increased, but significant, Newtonian resistance and
tissue dampening and elastance (Figure 13). These alterations in the AHR parameters,
together with an increase in inflammation, mucus secretions, and smooth muscle, are
suggestive of increased airway constriction and collapse following exposure to HDM
after Miro1 deletion, leading to worsened breathing.
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Figure 13. Conditional deletion of Miro1 from airway epithelium enhances airway
hyperresponsiveness in mouse lungs following chronic exposure to HDM.

Results from airway hyperresponsiveness initiation experiment, n = 6 mice per ∆EpiMiro1 HDM group and n = 4 for all other experimental groups from one experiment. * pvalue 0.05 vs corresponding PBS group, # p-value 0.05 vs Control HDM group. Error
bars represent mean ± SEM.
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2.4. Discussion
The results from this study show that deletion of Miro1 from club cells leads to
an increased inflammatory cell influx and enhanced secretion of pro-inflammatory
cytokines from epithelial cells, as well as the activation of pro-apoptotic markers
following chronic HDM exposure. Miro1 epithelial deletion also led to augmented mucus
metaplasia and pronounced remodeling in the airways. Finally, Miro1 deletion altered
lung mechanics following chronic allergen insult. The role of Miro1-mediated
mitochondrial trafficking upon exposure to a complex allergen in airway epithelial cells,
and their associated inflammatory responses, had not been demonstrated in previous
literature. Our results provide compelling evidence for the role of Miro1 in airway
epithelial cells by mediating inflammatory responses associated with HDM exposure.
However, the mechanistic details underlying the observed phenotype remains unclear.
Chronic inflammation of the lungs caused by aeroallergens such as HDM is a
hallmark of the pathophysiology associated with allergen-induced asthma [234]. In this
study, Miro1 was conditionally deleted from CCSP positive airway epithelial cells in
C57B/L6 mice. CCSP is predominantly expressed in club cells, a non-ciliated secretory
epithelial cell subtype that is ubiquitously expressed in murine lungs [58, 235]. ∆EpiMiro1 and control mice were sensitized, boosted, and exposed for 5 consecutive days in a
chronic model of allergen-induced inflammation to determine the role of Miro1 in HDMinduced lung inflammation. Our results show that epithelial deletion of Miro1 leads to an
inflammatory cell influx in the BALF, especially lymphocytes, as well as the increase of
pro-inflammatory mediators such as CCL20 and eotaxin in the whole tissue lysate
following HDM exposure. It is possible that the increase of CCL20, a lymphocyte and
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dendritic cell chemoattractant, and eotaxin, an eosinophil chemoattractant, leads to the
striking increase in inflammatory cells following Miro1 deletion in the lung tissue.
Specialized staining on the lung tissue would be beneficial to determine the inflammatory
cell profile in the observed sub-epithelial inflammation. In agreement with our work,
another study demonstrated that epithelial deletion of Miro1 leads to heightened proinflammatory responses following exposure to cigarette smoke [220]. However, the
inflammatory response in allergen-induced asthma is characterized by eosinophilia
associated with an increased number of T lymphocytes and mast cells. CD4+ T
lymphocytes regulate chronic inflammation in asthma via the release of Th2 adaptive
cytokines [236, 237], which can lead to the observed changes in airway
hyperresponsiveness, mucus production, and airway remodeling. Moreover, Miro1 plays
a critical role in signaling for mitophagy and interacting with the Pink1/Parkin
mitochondrial quality control system [238, 239], and compromised degradation of Parkin
has been shown to promote inflammation and the release of mtDNA [209]. However,
mitophagy can activate apoptotic signaling pathways [240-242], an observation we made
via the increase in the activity of caspases 3/7. Although we see non-significant increases
in the pro-inflammatory cytokines, Th2 adaptive cytokines, and inflammatory cell types
in situ, these should be measured in the serum to assess global changes of these markers.
Our data suggest that Miro1 regulates inflammatory responses, primarily lymphocyte
recruitment, following HDM exposure.
Airway remodeling has long been considered a cardinal feature of asthma that
results from longstanding inflammation and can lead to airway hyperresponsiveness
[243]. Structural changes within the airway wall such as epithelial membrane thickening,
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hypertrophy of smooth muscle cells, and peribronchial fibrosis result in the pathology
associated with asthma [244]. In this study, Miro1 deletion from epithelial cells led to
prominent airway remodeling changes resulting in increased collagen deposition,
heightened immune cell infiltration, and epithelial layer thickening, as demonstrated via
Masson’s trichrome staining. Miro1 deletion also led to increased smooth muscle
surrounding the perimetry of the airways, as shown through immunohistochemical
staining for α-smooth muscle actin. The observed increase in eotaxin in the whole tissue
lysate could be attributed to the increase in airway smooth muscle following Miro1
deletion, as airway smooth muscle has been shown to produce eotaxin and recruit
eosinophils from systemic circulation [245]. Moreover, other studies suggest that altered
calcium homeostasis that leads to increased mitochondrial biogenesis results in increased
bronchial smooth muscle mass [206]. It is possible that lack of appropriate mitochondrial
positioning following Miro1 deletion could lead to calcium level dysregulation and
increased airway smooth muscle. Together with our inflammatory cell profiles, these data
are suggestive that Miro1 helps attenuate inflammation-associated remodeling changes.
Mucus is primarily produced and secreted by goblet cells, a specific subset of
airway epithelial cells [51, 246]. Goblet cell hyperplasia and metaplasia has been
associated with asthma severity [99, 232], with mucus plugs being the primary cause of
death in asthma due to asphyxiation from intraluminal airway obstruction [233]. Our data
suggest that club cell specific deletion of Miro1 leads to augmented mucus metaplasia as
shown through the accumulation of mucus following exposure to HDM in the airway
epithelium. However, there were no increases in mucin protein levels in the BALF after
HDM exposure. Therefore, we hypothesize that mucins may remain in the secretory
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vesicles and not secreted into the intraluminal space following Miro1 deletion. Studies
have shown that ATP is required to initiate a signaling cascade that results in a Ca2+
triggered fusion of the mucin granules to the membranes [227-230]. Recent literature
examining the role of Miro1 during alveolar formation observed a similar phenomenon
where loss of epithelial Miro1 compromised the release of platelet-derived growth factor
[247]. We suspect that Miro1 expression leading to the appropriate positioning of
mitochondria in lung epithelial cells may be necessary for the secretion of mucins from
airway epithelial cells, preventing more severe asthma phenotypes. However, it is unclear
whether Miro1 deletion from club cells changes the functionality of mucus producing
cells if transdifferentiated, as murine asthma models have shown a dramatic shift in cell
phenotypes in the epithelium resulting from club cell differentiation to mucus cells [248].
The functional consequence of asthma is reversible airflow limitation [249].
Airway inflammation alone may cause airflow limitation or through inflammatory
mediators that act directly on airway smooth muscle [250]. Enhanced tissue remodeling
and mucus hyperplasia have been associated with increased airway hyperresponsiveness
[251, 252]. Our data show that Miro1 deletion from epithelial cells leads to changes in
airway mechanics independent of HDM exposure, suggesting intrinsic alterations within
the epithelium. The observed changes in airway hyperresponsiveness in this study could
be attributed to the heightened immune cell infiltration, mucus obstruction as a result of
goblet cell metaplasia, and enhanced smooth muscle levels and remodeling changes.
Results from this study suggest that Miro1-mediated mitochondrial trafficking
plays a role in the regulation of pro-inflammatory responses in the airway epithelium.
Deletion of Miro1 was shown to augment chronic HDM-induced inflammatory responses
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in the lungs, associated with pronounced inflammatory cell infiltration and remodeling
changes in the mouse lungs leading to altered lung mechanics. These results indicate a
possible role for Miro1 in the development and progression of inflammatory responses
and provide insights for the role of Miro1 in allergic airway diseases. Additional studies
should be conducted to elucidate the mechanisms leading to disease. Altogether, these
findings might have implications for the pharmacological targeting of Miro1 for the
management and treatment of allergic airway diseases.
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CHAPTER 3. DISCUSSION AND FUTURE DIRECTION
The goal of this study was to investigate the effects Miro1-mediated
mitochondrial trafficking in allergen-induced inflammation and provide a comprehensive
phenotypic readout. The results of this study show that epithelial deletion of Miro1 leads
to a modest heightened inflammatory response, enhanced mucus metaplasia, pronounced
tissue remodeling and increased smooth muscle levels that result in increased airway
hyperresponsiveness following chronic exposure to HDM. Altogether, our results
indicate a possible role for Miro1 in the development and progression of allergic asthma
and provide insights into the role of Miro1-mediated mitochondrial positioning in asthma
severity.
Our results show that Miro1 deletion from the epithelium results in a modest
increase of lymphocytes in the BALF following exposure to HDM. Likewise, an increase
in sub-epithelial inflammation was observed in the tissue. Specialized tissue staining
should be done to determine if the cell profiles present in the tissue correlate with the cell
populations seen in the BALF. Histological confirmation of lymphocyte populations
could be determined through CD45 staining of the lung tissue. Moreover, staining for
specific epithelial cell markers should also be conducted to assess if there are any
changes in the airway epithelial cell subtypes present before and after Miro1 deletion and
exposure to HDM. Staining tissue for KRT5, MUC5AC, β-tubulin IV, and CC10 for
basal cells, goblet cells, ciliated cells, and club cells – respectively – could provide
information about the role of Miro1 in cell trans-differentiation following HDM
exposure.
Furthermore, signs of epithelial barrier dysfunction, mainly pronounced
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invaginations stemming from the apical to the basolateral side of the epithelium, were
noted in the tissue of mice lacking Miro1 independent of HDM exposure. These
pronounced invaginations in the tissue could be due to disrupted adherens junctions,
which are responsible for cell-cell adhesions. E-cadherin, a Ca2+-dependent adhesion
molecule, is the primary adherens junction protein in the airways. Furthermore, Ecadherin is critical for epithelial barrier formation and for maintaining the apicalbasolateral polarization and adhesion to neighboring cells [81]. Evidence suggests that Ecadherin is disrupted in human pulmonary epithelial cell lines following HDM exposure
via the activation of PAR1 and/or PAR2 [253]. Other studies have shown that E-cadherin
deficient murine airways had an increased expression of α-smooth muscle actin, as well
as the progressive loss of airway epithelial cells, spontaneous mucus hypersecretion, and
eosinophilic airway inflammation [254]. We suspect that E-cadherin levels would be
decreased in mice lacking Miro1 exposed to HDM and that inappropriate mitochondrial
positioning following Miro1 deletion could alter the local calcium gradients leading to
the pronounced invaginations observed in the tissue. Moreover, proteins like CCSP,
which are abundant proteins in the extracellular lining fluid of the airways [255], could
be measured in the serum to see if there is any infiltration into systemic circulation as an
indirect measure of barrier dysfunction.
Our data also shows that Miro1 deletion from airway epithelial cells results in
subtle changes in lung mechanics that are suggestive of increased airway
hyperresponsiveness. These data show that there is a change in the lung tissue
independent of HDM exposure following Miro1 deletion. Unlike our results, a study by
Sharma et al. [220] suggests that epithelial deletion of Miro1 from airway epithelial cells
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led to changes in the mechanical properties in mice lacking Miro1 following cigarette
smoke exposure, as well as no significant airspace enlargement. Although our Flexivent
experiments provide valuable data regarding airway mechanics following Miro1 deletion,
other parameters such as respiratory capacity should be measured to assess any changes
in lung volumes. A study by Nguyen et al. [185] showed that global deletion of Miro1 in
mice caused postnatal lethality associated with unexpanded lungs, with post-mortem
examination of the lung tissue revealing a lack of alveoli expansion. Similarly, a recent
study by Zhang et al. [247] suggests that epithelial deletion of Miro1 results in the
disruption of alveolar formation. As alveolar numbers have been associated with total
lung volumes [256], we speculate that Miro1 deletion could result in reduced respiratory
capacity that is further altered following HDM exposure. However, it remains unknown
whether epithelial deletion of Miro1 affects lung volumes and the respiratory capacity of
mice following HDM exposure.
Moreover, given the severe phenotypes observed in our mouse model following
Miro1 deletion, it would be of interest to assess the expression of Miro1 in populations of
mild, moderate, and severe asthmatics to see if there are any correlations between Miro1
expression and disease severity. We suspect that Miro1 expression levels will be
diminished in those with more severe asthma. However, confirmation using cell cultures
should be done to see if Miro1 levels are reduced in our model. A study by Sundar et al.
[219] showed that Miro1 levels are significantly reduced in primary human lung
epithelial cells following chronic cigarette smoke exposure. Other studies using
mesenchymal stem cells have shown that overexpression of Miro1 leads to more efficient
mitochondrial transfer to epithelial cells, as well as epithelial tissue repair when
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compared to wild-type mesenchymal stem cells. Conversely, Miro1 knocked-out
mesenchymal cells lose their mitochondrial transfer capacity, and, as a result, lose their
healing abilities. Moreover, Ahmad et al. also demonstrated that overexpression of Miro1
in mesenchymal stem cells was linked to better therapeutic efficacy, as suggested by
reversal of airway hyperresponsiveness and remodeling in three separate models of
allergen-induced asthma [257].
Finally, screening for Miro1 mutations in severe asthmatics and other asthma
endotypes could also provide additional information about the role of Miro1 in the
development of asthma. A study by Grossmann et al. [193] showed heterozygous
mutations in the gene encoding for Miro1, RHOT1, in four individuals with Parkinson’s
disease. These mutations were located in highly conserved protein domains of Miro1.
The authors suggest that because of their position, calcium sensing and binding, GTP
hydrolysis, and localization features of Miro1 could be affected.
Altogether, our findings support a role for Miro1 in the exacerbation of
inflammatory responses and tissue reorganization in the context of allergic airway
diseases. Therefore, continued evaluation into the possible mutations to the Miro1 gene
and altered expression of the Miro1 protein in asthmatics is warranted in asthmatics.
Additionally, investigation into the regulation of the Miro1 gene via chromatin
modifications and transcription factor activation in the context of allergic asthma may
inform us of upstream control of Miro1 expression. In conclusion, Miro1 expression in
lung epithelial cells mediates inflammatory responses and tissue reorganization in a
mouse model of allergic asthma providing strong data and rationale for further
investigation into Miro1 and mitochondrial dynamics in allergic airway diseases.
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